On April 14, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17–22 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The research that Tempus is presenting at this year’s AACR (Free AACR Whitepaper) annual meeting underscores the scale and real-world impact of Tempus’ multimodal dataset and AI-enabled diagnostic solutions," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "Across these studies, our researchers are uncovering clinically relevant insights that not only deepen our understanding of tumor biology, but also have the potential to transform how cancer is diagnosed and treated. This work is a product of our ongoing commitment to advancing the field of oncology and, ultimately, to improving outcomes for the patients we serve."

Tempus will host an Exhibitor Spotlight Theater session on Monday, April 20, 2026, from 10:00–11:00 AM PST in Theater B of the Sails Pavilion. In "Beyond the Pilot: Scaling Multimodal AI and Lab-in-the-Loop for Breakthrough R&D," Sasser and Neil Bence, PhD, Senior Vice President of the Protein Homeostasis Thematic Research Center at Bristol Myers Squibb, will explore how combining deep molecular insights with high-throughput Lab-in-the-Loop functional screening can accelerate breakthroughs.

Tempus research highlights presented at this year’s conference include:

Co-occurrence of gene fusions and microsatellite instability (MSI) defines a clinically distinct subtype of colorectal cancer
Sunday, April 19, 2026, 2:00 – 5:00 PM PT
Section 20
Investigation into the co-occurrence of gene fusions and microsatellite instability (MSI) in 30,884,099 colorectal cancer patients revealed that clinically relevant fusions are significantly enriched in MSI versus MSS tumors (6.2% vs. 2.2%). These findings suggest that the clinical impact of gene fusions is mediated by MSI status, defining a distinct molecular subtype of colorectal cancer that may influence therapeutic stratification.
Oral Presentation: Real-world evidence of KMT2C mutation as a biomarker of sensitivity to platinum-based therapy in solid cancers
Monday, April 20, 2026, 2:30 – 4:30 PM PT
Room 14-Mezzanine Level – Convention Center
Researchers leveraged Tempus Lens to define a real-world cohort of 143,961 patients with solid tumors from the Tempus multimodal database. They sought to determine if KMT2C mutations are a biomarker for sensitivity to platinum-based chemotherapy (PBC). Their analysis revealed that patients with KMT2C mutations had significantly improved real-world overall survival (rwOS) after PBC treatment compared to patients without the mutation (19.6 vs. 16.7 months). The survival benefit was most significant in colorectal cancer (CRC), where patients with the mutation had a median rwOS of 51.0 months versus 25.3 months for those without. These findings, validated in the AACR (Free AACR Whitepaper) Genie dataset, support KMT2C as a predictive biomarker for platinum response—particularly in CRC and GI cancers—with laboratory studies underway to clarify mechanisms.
Analysis of RNA expression of 47 cell surface proteins in real-world small cell lung cancer patients
Tuesday, April 21 9:00 AM – 12:00 PM PT
Section 46
The research team performed an exploratory analysis of 56 cell surface proteins (CSPs) in 1,353 small cell lung cancer (SCLC) patients to identify differential expression patterns across subtypes, disease stages, and treatment statuses. Leveraging Tempus xT DNA-seq and xR RNA-seq data, the study identified subtype-specific expression.
Machine learning predicts retained retinoblastoma (Rb) function in real-world small cell lung cancer patients
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 46
To challenge the long-held belief that the retinoblastoma (RB) tumor suppressor is always inactive in small cell lung cancer (SCLC), the research team developed a machine learning model to predict RB function. Using genomic (Tempus xT) and transcriptomic (Tempus xR) data from a real-world cohort of approximately 1,400 SCLC patients, the model found that nearly 30% of patients with RB1 genomic alterations still showed evidence of RB function transcriptionally.
Immune-related RNA-seq biomarker-based clustering reveals heterogeneous immunotherapy responses and guides subtype-specific strategies in metastatic NSCLC
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 42
Patients with metastatic non-small cell lung cancer (mNSCLC) respond variably to first-line immunotherapy plus chemotherapy, yet the underlying immune biology driving these differences remains poorly understood. In a real-world cohort of 2,235 mNSCLC patients from the Tempus database, RNA-seq-based unsupervised clustering using immune markers identified four biologically distinct immune subtypes.
Validation of HER2, TROP2, and NECTIN4 IHC prediction algorithms for the ADC MATCH trial
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 6
To facilitate patient selection for the ADC MATCH clinical trial, investigators validated RNA-seq algorithms designed to identify patients likely to test positive for HER2, TROP2, and NECTIN4 via immunohistochemistry (IHC).
Detection of rare oncogenic fusions through concurrent DNA and RNA next-generation sequencing in a pan-cancer clinical setting
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 49
By retrospectively analyzing de-identified records from 74,182 patients with advanced cancer, this study quantified the clinical benefit of concurrent DNA and RNA testing for identifying rare oncogenic fusions.
Learn more about Tempus at AACR (Free AACR Whitepaper) Annual Meeting 2026.

(Press release, Tempus, APR 14, 2026, View Source [SID1234664375])

On April 14, 2026 Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of high-risk infections and pre-cancerous lesions caused by human papillomavirus (HPV) in women, reported expanded data from the company’s Phase 1b/2 clinical trial of ABI-2280 for the treatment of persistent oncogenic (high-risk) cervical HPV (hrHPV) infection in a Rapid Fire Oral Presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer April 10-13 in San Juan, Puerto Rico.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study achieved its primary endpoint and all secondary endpoints with the top dosing regimen of 1 mg dosed three times over two weeks for a cumulative dose of 3 mg. Patients receiving ABI-2280 demonstrated statistically significant improvements in the rate of hrHPV negativity at Week 12 and Week 24 as compared with placebo. Additionally, the trial showed ABI-2280 treatment to be safe and well tolerated with the most commonly reported adverse events (AEs) categorized as mild and moderate and localized to the treatment area.

Rapid Fire Oral Presentation Highlights (3mg Dosing Regimen):

For the primary efficacy endpoint, 46% of patients achieved hrHPV negativity at Week 12 for all hrHPV genotypes present at baseline as compared to only 16% of placebo patients (p=0.0077).
In a subgroup analysis of patients with the HPV16 genotype at baseline, 78% patients achieved HPV16 negativity at Week 12 and Week 24, compared to 0% and 25% of placebo patients at Week 12 and Week 24, respectively.
At Week 24, 65% of patients achieved hrHPV negativity for all hrHPV genotypes present at baseline as compared to only 32% of placebo patients (p=0.0127).
Week 12 data was highly predictive of Week 24; 100% of patients who were hrHPV negative at Week 12 following ABI-2280 treatment maintained hrHPV negativity at Week 24 suggesting the potential for durable viral clearance rather than transient suppression following just two weeks of treatment.
Patients in the study overall had a mean duration of hrHPV positivity at baseline of 29 months and 23.7% of patients had a persistent infection (defined as documented infection for >12 months) at baseline despite being previously vaccinated.
"Women with persistent high-risk HPV face a meaningful risk of disease progression to pre-cancer or cancer of the cervix, yet there are currently no approved treatment options. Patients are asked to ‘wait-and-see’ if the infection resolves or persists, while facing risks of disease progression and transmission to partners, creating significant psychosocial burden," said Warner K. Huh, MD, MSHA, presenting author and Chair of the Department of Obstetrics and Gynecology at the University of Alabama at Birmingham. "Against this backdrop, the data from the ABI-2280 study are clinically significant, demonstrating a 30 percent absolute improvement in hrHPV negativity compared with placebo, alongside a favorable safety and tolerability profile. Importantly, the durability of response observed is particularly encouraging and suggests the potential for ABI-2280 to maintain HPV at undetectable levels over extended periods of time."

The Phase 1b/2 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and efficacy of ABI-2280 administered intravaginally in women diagnosed with persistent cervical hrHPV infection. The study dosed a total of 139 female patients ranging in age between 25 and 55 years old who have had a documented hrHPV infection for at least one year without evidence of precancerous lesions worse than low grade cervical intraepithelial neoplasia (CIN1). Part A of the trial evaluated multiple placebo-controlled sentinel cohorts enrolled sequentially to determine the safety, tolerability and preliminary efficacy of various dose levels of ABI-2280 in two-week and six-week dosing regimens. Following the completion of the sentinel cohorts, the top cumulative dose from each of the two-week and six-week dosing regimens was advanced into Part B expansion cohorts for further evaluation of efficacy.

"We are encouraged by results from this study of ABI-2280, which we believe support advancing into a Phase 2b trial in women with persistent high-risk HPV infections," said Elaine Chien, MD, FACOG, Chief Medical Officer for Antiva. "The demonstration of clinically meaningful and statistically significant hrHPV negativity out to 24 weeks in our top dosing regimen, after only two weeks of treatment in women with a mean duration of infection exceeding two years, is particularly promising and informs a clear path forward. We are also pleased to have recently received FDA clearance of our Investigational New Drug (IND) application, which further enables the continued clinical development of ABI-2280."

ABI-2280 is expected to have potent activity across all genotypes of HPV worldwide and works by blocking HPV replication and inducing apoptosis in HPV-infected cells. Antiva has leveraged its development expertise to formulate a vaginal insert of ABI-2280 that enables at home self-administration at diagnosis.

About HPV-Related Diseases and Cervical Cancer

Human Papilloma Virus (HPV) is so common that nearly all sexually active men and women are infected with the virus at some point in their lives. Many of these are transient infections that the body is capable of clearing, but this typically takes months to years. When HPV infections persist, they are known to drive the formation of malignancies, including cervical, anal, vulvar, penile, and head and neck cancers.

The prevalence of cervical high-risk HPV (hrHPV) infection is estimated to be 20% among U.S. females of reproductive age, or approximately 19 million women. Each year in the U.S., it is estimated that over 6 million women become newly infected with hrHPV. There are currently no treatment options for hrHPV and these patients are counseled to wait and see if their infection clears or progresses to higher grade disease. During this wait and see period, patients are also at risk of transmitting this oncogenic virus to sexual partners. Approximately 30 percent of women with hrHPV fail to clear the virus within 12 months. These patients are considered to have persistent hrHPV and have an estimated 20 percent chance of having their infection progress to pre-cancer or cancer over the following four-to-six years. Women diagnosed with hrHPV often experience significant stress due to the social stigma of a sexually transmitted infection and the association with cervical cancer. The lack of available treatments further contributes to increased anxiety and emotional distress.

Globally, cervical cancer is the fourth most common cancer in women and as such represents a major public health problem. According to the World Health Organization, an estimated 660,00 women were diagnosed with cervical cancer worldwide and approximately 350,000 women died from the disease in 2022.

(Press release, Antiva Biosciences, APR 14, 2026, View Source [SID1234664374])

On April 14, 2026 ImmuVia Inc., a biotechnology company developing first-in-class therapies for solid tumors, reported that it has selected Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, as a strategic technology partner. ImmuVia will deploy Quantori’s Q-Scientist platform to streamline computational workflows across its preclinical programs, with the goal of compressing development timelines and reducing costs as it advances its lead candidate, IMV-M, towards clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Science: A New Approach to an Old Problem

Death Receptor agonists – molecules designed to trigger a tumor cell’s built-in self-destruct program (apoptosis) – have long been considered one of the most promising approaches in oncology. Yet clinical programs have failed, stymied by insufficient potency, off-target toxicity, or both.

ImmuVia’s proprietary Cancerlysin platform was built to solve this problem at the molecular level. Its lead candidate is IMV-M, a bispecific antibody that functions as a conditional switch: it first binds MUC16 – a protein overexpressed on ovarian, pancreatic, and other solid tumors – and only then activates the Death Receptor 5 pathway via clustering to trigger apoptosis. The result is a molecule specifically engineered for high-potency tumor killing with a wide therapeutic window.

The Partnership: Doing the Work Faster and at Lower Cost

The complexity of Cancerlysin programs generates significant computational demands across molecular modeling, pharmacokinetic simulation, and regulatory data preparation. Rather than build these capabilities in-house, ImmuVia has chosen to partner with Quantori, whose Q-Scientist platform provides an integrated environment for orchestrating these workflows. Under the partnership, Quantori will support ImmuVia’s preclinical programs in three key areas:

Molecular Modeling and Simulation: Running computational analyses of Cancerlysin molecules’ binding behavior and selectivity profile, reducing the number of iterative bench experiments required to optimize candidates.
In Silico Pharmacology: Modeling Cancerlysin molecule’s pharmacokinetic and pharmacodynamic properties across tumor microenvironments, enabling the team to test hypotheses computationally before committing to further costly in vivo studies.
Regulatory Data Preparation: Transforming high-volume laboratory and analytical data into structured, submission-ready documentation, compressing timelines for IND-enabling toxicology and CMC deliverables.
Executive Commentary

"ImmuVia is a biology company. Our edge is the science behind IMV-M and the Cancerlysin platform," said Iosif M. Gershteyn, Chief Executive Officer at ImmuVia. "What we need from technology partners is straightforward: help us do our work faster and at lower cost. Quantori’s platform does exactly that. It lets a lean team operate with the analytical throughput of a large organization, that’s a practical advantage we intend to leverage."

"What makes this collaboration compelling is the quality of the underlying science," said Yuriy Gankin, PhD, Chief Scientific Officer at Quantori. "ImmuVia’s platform represents a genuinely differentiated approach to harnessing the biology of apoptosis, and the computational demands of a program this sophisticated are exactly where Q-Scientist delivers the most value. We can construct detailed in silico models of IMV-M’s behavior – its conformational dynamics, its interactions within the tumor microenvironment – and deliver those insights at a speed and cost that would be impossible to replicate through traditional methods."

(Press release, ImmuVia, APR 14, 2026, View Source [SID1234664373])

On April 14, 2026 Brenus Pharma reported that new first‑in‑human data will be presented at the AACR (Free AACR Whitepaper) Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy.

Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show :

Favorable safety with no dose‑limiting toxicities (DLTs) observed.
Promising early efficacy, including 100% disease control rate (DCR) in RECIST.
Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses.
Exploratory analyses are ongoing to further characterize tumor–immune dynamics and identify predictive biomarkers supporting subsequent stages of clinical development.

Together, these results support continued advancement of STC‑1010 toward later‑stage evaluation and validate the SGC technology as a scalable, "off-the-shelf" approach for high unmet-need solid tumors.

Poster Details

Poster Title: "From preclinical models to first‑in‑human evaluation of STC‑1010 immunotherapy in unresectable advanced colorectal cancer"
Session: First‑in‑Human Phase I Clinical Trials
Date & Time: April 20, 2026 | 9:00 AM – 12:00 PM
Location: Poster Section 50
Poster Board Number: 11
Abstract Number: CT051

(Press release, Brenus Pharma, APR 14, 2026, View Source [SID1234664372])

On April 14, 2026 Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company reported the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Markets (GEM). Under the agreement, GEM intends to provide up to NT$500 million in terms of strategic funding to support Senhwa’s advancing pipeline, AI-enabled drug discovery initiatives, and global expansion strategy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This partnership highlights growing international investors’ confidence in Senhwa’s innovative R&D capabilities and its differentiated approach to integrating artificial intelligence into the development of its core assets. In addition to its ongoing focus on cancer immunotherapy, Senhwa has been actively building an AI-driven discovery platform. Through strategic collaboration with Y combinator backed AI Native company such as CellType, the Company is leveraging next-generation C2S (cell-to-sentence) technology to deepen mechanistic insights and systematically identify potential combination therapy in treating different types of cancers.

AI-enabled validation has demonstrated that Senhwa’s lead candidates possess promising immunomodulatory potential under specific tumor microenvironment conditions. These findings support the Company’s "cold-to-hot tumor" strategy, positioning Senhwa to capture opportunities in the next wave of immuno-oncology (IO 2.0). Mechanism-driven, AI-assisted drug development is rapidly emerging as a key investment theme across global pharmaceutical and capital markets.

Global Emerging Markets (GEM), headquartered in Luxembourg with offices in Paris, New York and Nassau (Bahamas), is a leading alternative investment group focused on emerging markets. GEM has completed over 590 transactions across 75 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profiles. Its family of funds and investment vehicles provide GEM and its partners with exposure to Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments.

Senhwa believes this strategic capital commitment will enable the Company to advance its clinical programs in parallel with its AI-driven discovery platform, further strengthening its competitive position within the global biopharmaceutical ecosystem. The partnership also lays a solid foundation for future international collaborations and potential commercialization opportunities.

(Press release, Senhwa Biosciences, APR 14, 2026, View Source [SID1234664371])